tradingkey.logo

ANI Pharmaceuticals Inc

ANIP

64.489USD

+0.559+0.87%
Horário de mercado ETCotações atrasadas em 15 min
1.40BValor de mercado
PerdaP/L TTM

ANI Pharmaceuticals Inc

64.489

+0.559+0.87%
Mais detalhes de ANI Pharmaceuticals Inc Empresa
ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company, which serves patients in need by developing, manufacturing and marketing branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset, Purified Cortrophin Gel, as well as its generics business with enhanced research and development capabilities. Its three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota, and one is located in East Windsor, New Jersey, are together capable of producing oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products. The Company has a commercial portfolio of approximately 118 products with a variety of indications and a robust portfolio of pipeline products.
Informações da empresa
Código da empresaANIP
Nome da EmpresaANI Pharmaceuticals Inc
Data de listagemMay 04, 2000
CEOMr. Nikhil Suresh Lalwani
Número de funcionários897
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 04
Endereço210 Main Street West
CidadeBAUDETTE
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal56623
Telefone12186343500
Sitehttps://www.anipharmaceuticals.com/
Código da empresaANIP
Data de listagemMay 04, 2000
CEOMr. Nikhil Suresh Lalwani
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
468.18K
+5.44%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
89.90K
-0.97%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
79.05K
+5.80%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
64.66K
-4.24%
Mr. Thomas J. (Tom) Haughey, J.D.
Mr. Thomas J. (Tom) Haughey, J.D.
Independent Director
Independent Director
55.86K
+8.42%
Mr. Thomas Andrew (Thom) Rowland
Mr. Thomas Andrew (Thom) Rowland
Senior Vice President, Head of Established Brands
Senior Vice President, Head of Established Brands
45.02K
+35.72%
Dr. Renee P. Tannenbaum, Pharm.D.
Dr. Renee P. Tannenbaum, Pharm.D.
Independent Director
Independent Director
26.96K
+19.17%
Mr. Matthew J. (Matt) Leonard
Mr. Matthew J. (Matt) Leonard
Independent Director
Independent Director
16.33K
+36.15%
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Nikhil Suresh Lalwani
Mr. Nikhil Suresh Lalwani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
468.18K
+5.44%
Mr. Chad Gassert
Mr. Chad Gassert
Senior Vice President - Corporate Development and Strategy
Senior Vice President - Corporate Development and Strategy
310.13K
+8.36%
Mr. Muthusamy Shanmugam
Mr. Muthusamy Shanmugam
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
Director, Head of Research and Development, Chief Operating Officer - Novitium Operations
92.59K
+12.47%
Mr. Ori Gutwerg
Mr. Ori Gutwerg
Senior Vice President - Generics
Senior Vice President - Generics
89.90K
-0.97%
Mr. Patrick D. Walsh
Mr. Patrick D. Walsh
Independent Chairman of the Board
Independent Chairman of the Board
79.05K
+5.80%
Ms. Krista Davis
Ms. Krista Davis
Chief Human Resources Officer, Senior Vice President
Chief Human Resources Officer, Senior Vice President
64.66K
-4.24%
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
Sem dados
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Sales of generic pharmaceutical products
98.68M
0.00%
Sales of rare disease pharmaceutical products
52.85M
0.00%
Sales of Cortrophin Gel
52.85M
0.00%
Sales of branded pharmaceutical products
29.48M
0.00%
Distribuição de ações
Atualizado em: sex, 16 de mai
Atualizado em: sex, 16 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
5.44%
Meridian Venture Partners
5.38%
Millennium Management LLC
5.16%
Global Alpha Capital Management Ltd.
3.40%
Other
69.35%
Investidores
Investidores
Proporção
BlackRock Institutional Trust Company, N.A.
11.27%
The Vanguard Group, Inc.
5.44%
Meridian Venture Partners
5.38%
Millennium Management LLC
5.16%
Global Alpha Capital Management Ltd.
3.40%
Other
69.35%
Tipos de investidores
Investidores
Proporção
Investment Advisor
41.99%
Investment Advisor/Hedge Fund
21.79%
Hedge Fund
20.04%
Research Firm
8.69%
Individual Investor
8.42%
Private Equity
5.38%
Corporation
2.94%
Bank and Trust
1.38%
Pension Fund
0.90%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
504
24.16M
111.60%
-1.18M
2025Q1
511
24.19M
111.77%
-1.42M
2024Q4
489
23.75M
109.53%
-1.38M
2024Q3
473
23.30M
110.79%
+2.44M
2024Q2
446
19.77M
94.29%
-402.06K
2024Q1
424
18.72M
89.20%
-877.00K
2023Q4
409
18.10M
88.69%
-881.29K
2023Q3
396
18.38M
91.57%
-127.77K
2023Q2
370
17.73M
90.91%
+852.82K
2023Q1
341
15.70M
87.63%
-1.26M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
BlackRock Institutional Trust Company, N.A.
2.44M
11.27%
-89.22K
-3.53%
Mar 31, 2025
The Vanguard Group, Inc.
1.18M
5.44%
-132.90K
-10.14%
Mar 31, 2025
Meridian Venture Partners
1.16M
5.38%
-255.00K
-17.97%
Mar 11, 2025
Millennium Management LLC
1.12M
5.16%
+298.32K
+36.45%
May 30, 2025
Global Alpha Capital Management Ltd.
735.59K
3.4%
+111.04K
+17.78%
Mar 31, 2025
Citadel Advisors LLC
723.33K
3.34%
+131.74K
+22.27%
Mar 31, 2025
State Street Global Advisors (US)
714.57K
3.3%
-22.72K
-3.08%
Mar 31, 2025
Deep Track Capital LP
700.00K
3.23%
+50.96K
+7.85%
Mar 31, 2025
Esjay L.L.C,
632.62K
2.92%
-200.00K
-24.02%
Mar 14, 2025
Dimensional Fund Advisors, L.P.
631.56K
2.92%
-54.17K
-7.90%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 2 de ago
Atualizado em: sáb, 2 de ago
Nome
Proporção
Invesco Pharmaceuticals ETF
3.03%
SPDR S&P Pharmaceuticals ETF
2.41%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.71%
Invesco S&P SmallCap Health Care ETF
0.79%
iShares U.S. Pharmaceuticals ETF
0.56%
First Trust Small Cap Growth AlphaDEX Fund
0.54%
Invesco S&P SmallCap 600 Pure Growth ETF
0.46%
VictoryShares US Small Mid Cap Value Momentum ETF
0.38%
First Trust Small Cap Core Alphadex Fund
0.29%
First Trust Active Factor Small Cap ETF
0.24%
Ver Mais
Invesco Pharmaceuticals ETF
Proporção3.03%
SPDR S&P Pharmaceuticals ETF
Proporção2.41%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.71%
Invesco S&P SmallCap Health Care ETF
Proporção0.79%
iShares U.S. Pharmaceuticals ETF
Proporção0.56%
First Trust Small Cap Growth AlphaDEX Fund
Proporção0.54%
Invesco S&P SmallCap 600 Pure Growth ETF
Proporção0.46%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporção0.38%
First Trust Small Cap Core Alphadex Fund
Proporção0.29%
First Trust Active Factor Small Cap ETF
Proporção0.24%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
KeyAI